| scholarly article | Q13442814 |
| P50 | author | W. Martin Kast | Q78138546 |
| P2093 | author name string | Shabaana A Khader | |
| Javier Rangel-Moreno | |||
| Norma Ofelia Uribe-Uribe | |||
| María de la Luz García-Hernández | |||
| Ricardo Espinosa-González | |||
| P2860 | cites work | CXCR5⁺ T helper cells mediate protective immunity against tuberculosis | Q24628780 |
| Inflammation and cancer | Q24649640 | ||
| Tertiary Lymphoid Organs in Cancer Tissues | Q26742168 | ||
| The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements | Q26750672 | ||
| Therapeutic Lymphoid Organogenesis in the Tumor Microenvironment | Q26799123 | ||
| Regulation of immune responses by prostaglandin E2 | Q26849305 | ||
| Global cancer statistics, 2012 | Q27860501 | ||
| Immunity, Inflammation, and Cancer | Q27861048 | ||
| Understanding Immune Cells in Tertiary Lymphoid Organ Development: It Is All Starting to Come Together | Q28067648 | ||
| Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention | Q28073895 | ||
| Complementary effects of TNF and lymphotoxin on the formation of germinal center and follicular dendritic cells | Q28140671 | ||
| Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate | Q28209919 | ||
| Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival | Q29547865 | ||
| Angiogenesis in health and disease | Q29614541 | ||
| The immune contexture in human tumours: impact on clinical outcome | Q29620667 | ||
| Regulatory T cells: mechanisms of differentiation and function | Q29620731 | ||
| Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules | Q30047232 | ||
| Bronchus-associated lymphoid tissue (BALT) and survival in a vaccine mouse model of tularemia | Q33618911 | ||
| Inflammation and oncogenesis: a vicious connection | Q33653294 | ||
| Lymphoid neo-organogenesis: lymphotoxin's role in inflammation and development | Q33735993 | ||
| Assessment of tumor vascularization: immunohistochemical and non-invasive methods | Q33835172 | ||
| Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression | Q33862487 | ||
| Synergistic up-regulation of CXCL10 by virus and IFN γ in human airway epithelial cells | Q33916203 | ||
| The development of inducible bronchus-associated lymphoid tissue depends on IL-17. | Q34191942 | ||
| Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. | Q34586903 | ||
| Regulatory T cells interfere with the development of bronchus-associated lymphoid tissue | Q34610191 | ||
| Development of secondary lymphoid organs | Q34764895 | ||
| Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes | Q35013272 | ||
| Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients | Q35170144 | ||
| CXCR3 chemokine receptor enables local CD8(+) T cell migration for the destruction of virus-infected cells | Q35193773 | ||
| Coordinated regulation of lymph node vascular-stromal growth first by CD11c+ cells and then by T and B cells. | Q35566574 | ||
| Enhanced central memory cluster of differentiation 8(+) and tumor antigen-specific T cells in prostate cancer patients receiving repeated in situ adenovirus-mediated suicide gene therapy | Q35753616 | ||
| Lymphoid tissue homing chemokines are expressed in chronic inflammation | Q35810009 | ||
| Pulmonary expression of CXC chemokine ligand 13, CC chemokine ligand 19, and CC chemokine ligand 21 is essential for local immunity to influenza | Q35973395 | ||
| Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. | Q36134167 | ||
| Regulation of lymph node vascular growth by dendritic cells. | Q36228770 | ||
| Chronic inflammation caused by lymphotoxin is lymphoid neogenesis | Q36366337 | ||
| Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma | Q36377337 | ||
| Tumor-infiltrating T lymphocytes: friends or foes? | Q36381918 | ||
| B lymphocytes induce the formation of follicular dendritic cell clusters in a lymphotoxin alpha-dependent fashion. | Q36400576 | ||
| Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma | Q36853440 | ||
| Synergistic COX2 Induction by IFNγ and TNFα Self-Limits Type-1 Immunity in the Human Tumor Microenvironment | Q36928855 | ||
| Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy | Q36944371 | ||
| Cyclooxygenase-2 (COX-2): a molecular target in prostate cancer | Q37022652 | ||
| Ectopic lymphoid tissues and local immunity | Q37075235 | ||
| Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours | Q37610628 | ||
| Cancer cell-secreted IGF2 instigates fibroblasts and bone marrow-derived vascular progenitor cells to promote cancer progression. | Q37642862 | ||
| Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates Apatinib treatment efficacy in gastric cancer | Q37707033 | ||
| Role of lymphotoxin and homeostatic chemokines in the development and function of local lymphoid tissues in the respiratory tract. | Q37765477 | ||
| Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy. | Q37898911 | ||
| Tertiary lymphoid organs in infection and autoimmunity | Q38012568 | ||
| History of myeloid-derived suppressor cells | Q38141522 | ||
| Tumour-induced immune suppression: role of inflammatory mediators released by myelomonocytic cells. | Q38193589 | ||
| Ectopic lymphoid-like structures in infection, cancer and autoimmunity | Q38221815 | ||
| Tertiary lymphoid structures in cancer and beyond | Q38274486 | ||
| Higher numbers of T-bet(+) intratumoral lymphoid cells correlate with better survival in gastric cancer | Q38400261 | ||
| The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System | Q38613858 | ||
| IL-17-induced CXCL12 recruits B cells and induces follicle formation in BALT in the absence of differentiated FDCs | Q38641655 | ||
| Cell-cycle-dependent drug-resistant quiescent cancer cells induce tumor angiogenesis after chemotherapy as visualized by real-time FUCCI imaging. | Q38742078 | ||
| NCR(+)ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures. | Q38833469 | ||
| Lymphoid Neogenesis and Tertiary Lymphoid Organs in Transplanted Organs. | Q39084586 | ||
| Pulmonary expression of oncostatin M (OSM) promotes inducible BALT formation independently of IL-6, despite a role for IL-6 in OSM-driven pulmonary inflammation | Q39135592 | ||
| Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion | Q39413746 | ||
| Helicobacter-induced chronic active lymphoid aggregates have characteristics of tertiary lymphoid tissue | Q39755242 | ||
| High endothelial venules are rare in colorectal cancers but accumulate in extra-tumoral areas with disease progression. | Q39832756 | ||
| Regulatory T cells prevent inducible BALT formation by dampening neutrophilic inflammation. | Q41157946 | ||
| T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion | Q41400520 | ||
| Reducing prostaglandin E2 production to raise cancer immunogenicity | Q42128543 | ||
| COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells | Q42323954 | ||
| The role of prostaglandin E2 in the immunopathogenesis of experimental pulmonary tuberculosis. | Q44016592 | ||
| Distinct role of surface lymphotoxin expressed by B cells in the organization of secondary lymphoid tissues | Q44158648 | ||
| Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity | Q45018410 | ||
| Activated human B lymphocytes express cyclooxygenase-2 and cyclooxygenase inhibitors attenuate antibody production | Q45280795 | ||
| Evidence for the antagonistic form of CXC-motif chemokine CXCL10 in serous epithelial ovarian tumours | Q45768686 | ||
| In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. | Q46004345 | ||
| Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. | Q46655434 | ||
| Role of CXC chemokine ligand 13, CC chemokine ligand (CCL) 19, and CCL21 in the organization and function of nasal-associated lymphoid tissue | Q47714667 | ||
| The composition of ectopic lymphoid structures suggests involvement of a local immune response in cardiac allograft vasculopathy. | Q50753444 | ||
| Characterisation of Tertiary Lymphoid Organs in Explanted Rejected Donor Kidneys. | Q53229165 | ||
| The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. | Q53646174 | ||
| Prognostic Value of Intratumoral Interferon Gamma Messenger RNA Expression in Invasive Cervical Carcinomas | Q56966580 | ||
| Sustained interleukin‐6 signalling leads to the development of lymphoid organ‐like structures in the lung | Q64377813 | ||
| "Evanescent" prostate carcinoma | Q73234115 | ||
| Vascular endothelial growth factor content in metastasizing and nonmetastasizing Dunning prostatic adenocarcinoma | Q74229290 | ||
| The prostate-associated lymphoid tissue (PALT) is linked to the expression of homing chemokines CXCL13 and CCL21 | Q80251740 | ||
| Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity | Q80620427 | ||
| Another TLO in the Wall: Education and Control of T Cells in Atherosclerotic Arteries | Q85396527 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P921 | main subject | prostate cancer | Q181257 |
| tertiary lymphoid organ | Q108017266 | ||
| P304 | page(s) | 563 | |
| P577 | publication date | 2017-05-17 | |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | A Unique Cellular and Molecular Microenvironment Is Present in Tertiary Lymphoid Organs of Patients with Spontaneous Prostate Cancer Regression | |
| P478 | volume | 8 |
| Q91330015 | BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration |
| Q91812276 | Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting |
| Q92410897 | Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy |
| Q92424711 | Multiscale engineering of immune cells and lymphoid organs |
| Q54947404 | Spontaneous regression of a primary squamous cell lung cancer following biopsy: a case report. |
| Q64057061 | Strategies for developing and optimizing cancer vaccines |
| Q47194123 | Tertiary Lymphoid Structures in Cancer: Drivers of Antitumor Immunity, Immunosuppression, or Bystander Sentinels in Disease? |
| Q58746430 | Tertiary Lymphoid Structures: Autoimmunity Goes Local |
| Q92052710 | Tertiary lymphoid structures in the era of cancer immunotherapy |
| Q90050585 | The Crohn's-Like Lymphoid Reaction to Colorectal Cancer-Tertiary Lymphoid Structures With Immunologic and Potentially Therapeutic Relevance in Colorectal Cancer |
| Q57468602 | The genomic basis of tumor regression in Tasmanian devils (Sarcophilus harrisii) |
| Q93182663 | The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer |
Search more.